Treatment-related mortality with everolimus in cancer patients.
about
Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysisSafety of mTOR inhibitors in breast cancer.Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity.mTor Inhibitors for the Treatment of Endometriosis.Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
P2860
Treatment-related mortality with everolimus in cancer patients.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Treatment-related mortality with everolimus in cancer patients.
@ast
Treatment-related mortality with everolimus in cancer patients.
@en
type
label
Treatment-related mortality with everolimus in cancer patients.
@ast
Treatment-related mortality with everolimus in cancer patients.
@en
prefLabel
Treatment-related mortality with everolimus in cancer patients.
@ast
Treatment-related mortality with everolimus in cancer patients.
@en
P2093
P2860
P1433
P1476
Treatment-related mortality with everolimus in cancer patients
@en
P2093
Charles L Shapiro
Erin R Macrae
Maria Paskell
Maryam Lustberg
Robert Wesolowski
P2860
P304
P356
10.1634/THEONCOLOGIST.2013-0355
P577
2014-05-02T00:00:00Z